BRAF and melanoma: In another phase III, randomized, controlled clinical trial, in which the efficacy of dacarbazine was compared with the BRAF inhibitor dabrafenib, similar results were obtained in terms of PFS and OS in advanced-stage previously untreated melanoma patients harboring BRAF exon 15 p.V600 point mutations (p.V600E and p.V600K) [139,140].